Cargando…

The in-use stability of the rituximab biosimilar Rixathon®/Riximyo® upon preparation for intravenous infusion

PURPOSE: The purpose of this study was to evaluate the in-use physicochemical and biological stability of the Sandoz rituximab biosimilar, marketed under the trade names Rixathon® and Riximyo® in the European Union, upon preparation for intravenous infusion. METHODS: Three batches of Rixathon®/Rixim...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lamanna, William C, Heller, Katharina, Schneider, Daniel, Guerrasio, Raffaele, Hampl, Veronika, Fritsch, Cornelius, Schiestl, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348458/ https://www.ncbi.nlm.nih.gov/pubmed/28950806 http://dx.doi.org/10.1177/1078155217731506

Ejemplares similares

Study of the Stability of Sandoz Rituximab Biosimilar Rixathon(®)/Riximyo(®) When Subjected for up to 21 Days to Ambient Storage
por: Borišek, Roman, et al.
Publicado: (2022)

Physicochemical and Functional Comparability Between the Proposed Biosimilar Rituximab GP2013 and Originator Rituximab
por: Visser, Jan, et al.
Publicado: (2013)

Ultrafast 30‐min infusion of a rituximab biosimilar (Truxima)
por: Pérez‐Persona, Ernesto, et al.
Publicado: (2023)

Factors Influencing Infusion-Related Reactions Following Dosing of Reference Rituximab and PF-05280586, a Rituximab Biosimilar
por: Courville, Jocelyn, et al.
Publicado: (2021)

PB2701: SAFETY OF 30 MINUTES INFUSION OF RITUXIMAB BIOSIMILAR. A COHORT STUDY.
por: Palomares, Laida Cuevas, et al.
Publicado: (2023)

Biosimilars Have Arrived: Rituximab
por: Greenwald, Maria, et al.
Publicado: (2018)

Budget Impact Analysis of the Introduction of Rituximab and Trastuzumab Intravenous Biosimilars to EU-5 Markets
por: Jang, Minyoung, et al.
Publicado: (2020)

Biologicals and Biosimilars in Hematology: The Case of Rituximab
por: Vulto, Arnold G.
Publicado: (2019)

Rituximab biosimilars open new horizons in immunotherapy
por: Jaeger, Ulrich
Publicado: (2017)

Efficacy and safety of rituximab biosimilar in refractory lupus
por: Pongtarakulpanit, Nantakarn, et al.
Publicado: (2020)

Introduction of Biosimilar Rituximab: A Hospital Perspective
por: Cheesman, Simon
Publicado: (2020)

Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
por: Waller, Cornelius F., et al.
Publicado: (2021)

Time Savings with Rituximab Subcutaneous Injection versus Rituximab Intravenous Infusion: A Time and Motion Study in Eight Countries
por: De Cock, Erwin, et al.
Publicado: (2016)

Safety of switching between rituximab biosimilars in onco-hematology
por: Urru, Silvana A. M., et al.
Publicado: (2021)

REFLECT: prospective multicenter non-interventional study evaluating the effectiveness and safety of Sandoz rituximab (SDZ-RTX; Rixathon(®)) in combination with CHOP for the treatment of patients with previously untreated CD20-positive diffuse large B-cell lymphoma
por: Welslau, Manfred, et al.
Publicado: (2023)

Extrapolation concept at work with biosimilar: a decade of experience in oncology
por: Krendyukov, Andriy, et al.
Publicado: (2018)

Rituximab Biosimilar Prevents Poor Outcomes of Microscopic Polyangiitis and Granulomatosis with Polyangiitis as Effectively as Rituximab Originator
por: Kwon, Hyeok Chan, et al.
Publicado: (2020)

Assessing the Extended In-Use Stability of the Infliximab Biosimilar PF-06438179/GP1111 Following Preparation for Intravenous Infusion
por: Vimpolsek, Maja, et al.
Publicado: (2019)

Ten years of biosimilars in Europe: development and evolution of the regulatory pathways
por: Schiestl, Martin, et al.
Publicado: (2017)

The ESMO position paper on biosimilars in oncology: enhancing the provision of accurate education and information
por: Schiestl, Martin, et al.
Publicado: (2017)

Safety and tolerability of a 90‐minute rapid infusion of Sandoz biosimilar rituximab in B‐cell lymphoproliferative disorders in a real‐world setting
por: Muntañola, Ana, et al.
Publicado: (2022)

Rituximab in the treatment of follicular lymphoma: the future of biosimilars in the evolving therapeutic landscape
por: Subramanian, Janakiraman, et al.
Publicado: (2017)

SEVERE ADENOVIRUS PNEUMONIA IN RITUXIMAB INFUSIONS
por: BJORK, SARAH, et al.
Publicado: (2021)

Extension Study of PF‐05280586, a Potential Rituximab Biosimilar, Versus Rituximab in Subjects With Active Rheumatoid Arthritis
por: Cohen, Stanley B., et al.
Publicado: (2018)

Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years’ Experience Gained
por: Aapro, Matti, et al.
Publicado: (2018)

Comparative assessment of clinical response in patients with rheumatoid arthritis between PF‐05280586, a proposed rituximab biosimilar, and rituximab
por: Williams, Jason H., et al.
Publicado: (2016)

Real-world experience of rituximab biosimilar GP2013 in rheumatoid arthritis patients naïve to or switched from reference rituximab
por: Łosińska, Katarzyna, et al.
Publicado: (2023)

Infusion reaction to infliximab biosimilar after transitioning from infliximab
por: Kashlan, Reem, et al.
Publicado: (2020)

Target-directed development and preclinical characterization of the proposed biosimilar rituximab GP2013
por: da Silva, Antonio, et al.
Publicado: (2014)

Cost-effectiveness of obinutuzumab versus rituximab biosimilars for previously untreated follicular lymphoma
por: Spencer, Scott J, et al.
Publicado: (2021)

Rapid Infusion Rituximab for Maintenance Therapy: Is It Feasible?
por: Patel, Jolly, et al.
Publicado: (2013)

Allergic/infusion reactions reported with cetuximab and rituximab
por: Wolf, Ray A, et al.
Publicado: (2015)

Massive Intravenous Infusions
por: Harrison, William, et al.
Publicado: (1954)

Continuous Intravenous Infusion
por: Farquharson, Eric L.
Publicado: (1934)

Rapid infusion of infliximab biosimilars and the incidence and severity of infusion‐related reactions in patients with inflammatory bowel disease
por: Rusch, Caroline, et al.
Publicado: (2022)

Analytical similarity assessment of rituximab biosimilar CT-P10 to reference medicinal product
por: Lee, Kyoung Hoon, et al.
Publicado: (2018)

Intensive Safety Monitoring of Rituximab (Biosimilar Novex(®) and the Innovator) in Pediatric Patients With Complex Diseases
por: Riva, Natalia, et al.
Publicado: (2022)

The Path Towards a Tailored Clinical Biosimilar Development
por: Schiestl, Martin, et al.
Publicado: (2020)

P1224: EFFICACY OF RITUXIMAB AND BIOSIMILAR RITUXIMAB IN UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA, A DANISH POPULATION BASED ANALYSIS
por: Haujir, A., et al.
Publicado: (2022)

Acute Respiratory Distress Syndrome after Rituximab Infusion
por: Montero, Alberto J., et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_phn4v57jufhan3cn1pm77fjkh6